Featured 13F manager
Paulson & Co. Inc. John Paulson
Jersey City, NJ 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $2.6B
- 8 Positions
- 2026 Q2
- −17.2% QoQ
- Top 5 92.3%
John Paulson files Paulson & Co. Inc. as a Form 13F. The latest book is 2026 Q2 at $2.6B, down 17.2% QoQ, led by Madrigal Pharmaceuticals, Perpetua Resources, and Acadian Asset Management.
Portfolio
top 5 92.3% · top 10 100.0%
- MDGL - Madrigal Pharmaceuticals 27.9%
- PPTA - Perpetua Resources 26.1%
- AAMI - Acadian Asset Management 16.2%
- BHC - Bausch Health Cos 14.0%
- THM — 8.1%
- NG - Novagold Resources 6.3%
- THRY - Thryv 1.3%
- GOOGL - Alphabet · CL A 0.1%
AUM over time
Book
| MDGL - Madrigal Pharmaceuticals | 31.44% | Reduce −0.5% | 2,089,523 | $302.64 | $632M | −10,000 | −$63M |
| PPTA - Perpetua Resources | 19.53% | Add +30.6% | 32,347,299 | $12.14 | $393M | +7,575,757 | +$128M |
| AAMI - Acadian Asset Management | 15.68% | Hold | 8,950,121 | $35.24 | $315M | — | — |
| BHC - Bausch Health Cos | 10.86% | Add +24.0% | 32,791,702 | $6.66 | $218M | +6,352,667 | +$47M |
| NG - Novagold Res | 5.54% | Hold | 27,238,061 | $4.09 | $111M | — | — |
| AEM - Agnico Eagle Mines | 4.63% | Hold | 783,561 | $118.93 | $93M | — | — |
| THM — | 2.99% | Hold | 70,239,388 | $0.8555 | $60M | — | — |
| THRY - Thryv | 2.59% | Hold | 4,280,000 | $12.16 | $52M | — | — |
| HON - Honeywell Intl | 2.32% | Hold | 200,000 | $232.88 | $47M | — | — |
| SA - Seabridge Gold | 1.49% | Hold | 2,070,000 | $14.52 | $30M | — | — |
| Trilogy Metals | 0.96% | Hold | 14,326,996 | $1.35 | $19M | — | — |
| EQX - Equinox Gold | 0.71% | Hold | 2,500,000 | $5.75 | $14M | — | — |
| Iamgold | 0.68% | Hold | 1,850,000 | $7.35 | $14M | — | — |
| Juniper Networks | 0.50% | New | 250,000 | $39.93 | $10M | +250,000 | +$10M |
| GOOG - Alphabet · CL C | 0.08% | New | 9,000 | $177.39 | $2M | +9,000 | +$2M |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Intra-Cellular Therapies | 0.16% | Exit | 0 | $131.91 | $3M | −21,500 | −$3M |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 8 | $2.6B | −17.2% | 13F-HR | 8/14/2026 | 000101359426000913 |
| 2026 Q1 | 9 | $3.1B | −4.6% | 13F-HR | 5/15/2026 | 000101359426000611 |
| 2025 Q4 | 9 | $3.3B | +9.9% | 13F-HR | 2/17/2026 | 000101359426000257 |
| 2025 Q3 | 10 | $3B | +47.6% | 13F-HR | 11/14/2025 | 000101359425001436 |
| 2025 Q2 | 15 | $2B | +15.1% | 13F-HR | 8/14/2025 | 000101359425001044 |
| 2025 Q1 | 14 | $1.7B | +5.8% | 13F-HR | 5/15/2025 | 000101359425000679 |
| 2024 Q4 | 13 | $1.7B | +15.9% | 13F-HR | 2/14/2025 | 000101359425000309 |
| 2024 Q3 | 15 | $1.4B | +5.3% | 13F-HR | 11/14/2024 | 000101359424000980 |
| 2024 Q2 | 16 | $1.4B | −6.6% | 13F-HR | 8/14/2024 | 000101359424000667 |
| 2024 Q1 | 18 | $1.4B | +30.7% | 13F-HR | 5/15/2024 | 000101359424000487 |
| 2023 Q4 | 17 | $1.1B | −0.9% | 13F-HR | 2/14/2024 | 000101359424000197 |
| 2023 Q3 | 18 | $1.1B | +9.2% | 13F-HR | 11/14/2023 | 000101359423000930 |
| 2023 Q2 | 21 | $1B | −14.9% | 13F-HR | 8/14/2023 | 000101359423000696 |
| 2023 Q1 | 20 | $1.2B | +8.3% | 13F-HR | 5/15/2023 | 000101359423000494 |
| 2022 Q4 | 22 | $1.1B | −18.7% | 13F-HR | 2/14/2023 | 000101359423000262 |
| 2022 Q3 | 28 | $1.4B | −32.6% | 13F-HR | 11/14/2022 | 000156761922020074 |
| 2022 Q2 | 32 | $2B | −37.6% | 13F-HR | 8/15/2022 | 000156761922016238 |
| 2022 Q1 | 33 | $3.2B | +0.2% | 13F-HR | 5/16/2022 | 000156761922011018 |
| 2021 Q4 | 36 | $3.2B | −7.6% | 13F-HR | 2/14/2022 | 000156761922004409 |
| 2021 Q3 | 38 | $3.5B | — | 13F-HR | 11/15/2021 | 000156761921020479 |
About
Paulson & Co. Inc.
20 processed 13Fs on this site · 2021 Q3–2026 Q2